[1]Patent:US2004/162285,2004,A1
[1]CurrentPatentAssignee:ROCHEHOLDINGAG-WO2008/124450,2008,A1
[2]CurrentPatentAssignee:CANCERTHERAPEUTICSCRCPTYLTD-WO2019/43139,2019,A1
[1]Patent:WO2019/43139,2019,A1.Locationinpatent:Page/Pagecolumn56
63636-89-5
64356-57-6
1698428-16-8
2230800-15-2
1603480-24-5 | 3-propylbenzene-1-sulfonyl chloride | AA01B3KB | MFCD29939542
1391737-94-2 | 5-bromo-2-cyclopropyl-1,3-oxazole | AA01B3X2 | MFCD22682027
1785570-41-3 | 4-Bromo-1,1-difluoro-3,3-dimethylbutane | AA01B4R5 | MFCD28526011
1508538-10-0 | 2-[5-(1H-pyrrol-2-yl)-1,3,4-oxadiazol-2-yl]ethan-1-ol | AA01B4V6 | MFCD26599715
198334-36-0 | 4-(furan-2-yl)piperidine hydrochloride | AA01B4YZ | MFCD02178918
339363-85-8 | 1-[(2-Bromoethyl)sulfanyl]-4-fluorobenzene | AA01B54N | MFCD09944899
1955506-69-0 | methyl 1-acetyl-3-(benzyloxy)cyclobutane-1-carboxylate | AA01B58H | MFCD30181021
1211505-65-5 | {thieno[2,3-c]pyridin-2-yl}methanol | AA01B5D5 | MFCD18453120
1342007-75-3 | 1-Hydroxy-3,3-dimethylcyclohexanecarboxylic acid | AA01B5H9 | MFCD20328739
1955553-05-5 | 7,7-difluoro-2-oxabicyclo[4.1.0]heptane-1-carbonitrile | AA01B5L4 | MFCD30181157